natgillin/translations-raw huggingface dataset:
Passende nødhjælpsforanstaltninger skal være let tilgængelige, når intravenøs injektion med ibandonsyre administreres.
Appropriate medical support and monitoring measures should be readily available when ibandronic acid intravenous injection is administered.
Passende regulering af den immunsupprimerende behandling bør overvejes hos patienter med forhøjede serum- kreatininniveauer.
Appropriate adjustment of the immunosuppression regimen should be considered in patients with elevated serum creatinine levels.
Passende screeningsundersøgelser (dvs.tuberkulinhudtest og røntgen af thorax) bør foretages hos alle patienter (i henhold til lokale anbefalinger).
Appropriate screening tests (i.e. tuberculin skin test and chest X-ray) should be performed in all patients (local recommendations may apply).
Passende screeningundersøgelser, såsom tuberkulin test og røntgen af thorax, bør udføres hos alle patienter (lokale vejledninger kan væ re gæ ldende).
Appropriate screening tests, i.e. tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply).
Passende screeningundersøgelser, såsom tuberkulin test og røntgen af thorax, bør udføres hos alle patienter (lokale vejledninger kan være gældende).
Appropriate screening tests, i.e. tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply).
Passende screeningundersøgelser, såsom tuberkulintest og røntgen af thorax, bør udføres hos alle patienter (lokale vejledninger kan være gældende).
Appropriate screening tests, i.e. tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply).
Passendeklinisk monitorering tilrådes i overensstemmelse med anvendte antipsykotiske vejledninger, som f.eks. måling af blodsukker ved baseline, 12 uger efter start på olanzapinbehandling og derefter årligt.
Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines, e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter.
Passiv immunisering af afkommet fra vaccinerede gylte og søer til forebyggelse af dødelighed og kliniske symptomer på Aujeszkys sygdom og til reducering af udskillelse af naturligt forekommende Aujeszkys sygdomsvirus.
Passive immunisation of the progeny of vaccinated gilts and sows to reduce mortality and clinical signs of Aujeszky’s disease and to reduce the excretion of Aujeszky’s disease field virus.
Passiv immunisering af smågrise fra vaccinerede gylte og søer for at reducere dødelighed og kliniske symptomer på Aujeszkys sygdom og for at reducere udskillelsen af naturligt forekommende Aujeszkys sygdomsvirus.
Passive immunisation of piglets from vaccinated gilts and sows to reduce mortality and clinical signs of Aujeszky’s disease and to reduce the excretion of Aujeszky’s disease field virus.
Passiv overførsel af antistoffer mod erytrocyt-antigener, f.eks.
Passive transmission of antibodies to erythrocyte antigens, e.g.
Passiv overførsel af antistoffer mod erytrocytantigener, f.eks.
Passive transmission of antibodies to erythrocyte antigens, e.g.
Passiv overførsel af antistoffer til røde blodlegemers antigener, f.eks.
Passive transmission of antibodies to erythrocyte antigens, e.g.
Pateinterne får udleveret et særligt informationskort med sikkerhedsoplysninger, som de bør bære på sig.
Patients will be given a special patient alert card with safety information that patients should carry on them.
PaTH-studiet var et National Institute of Health (NIH) sponsoreret, randomiseret, placebokontrolleret, 2-årigt, multicenter, dobbeltblindet studie med Preotact og alendronat som monoterapi eller kombinationsterapi til behandling af postmenopausal osteoporose.
The PaTH study was a National Institute of Health (NIH) sponsored randomised, placebo-controlled, 2 year, multicenter, double-blind trial of Preotact and alendronate as monotherapy and in combination for the treatment of postmenopausal osteoporosis.
Patie nte r med højt blodtryk
Patie nts with high blood pre ssure
Patie nte r med højt blodtryk og type 2-diabe tes med nyre sygom
Patie nts with high blood pre ssure and type 2 diabe tes with kidne y disease
Patient - Global
Patient Global
Patient informationskort
Patient Alert Card
Patient udvælgelseskriterier, herunder at Pioglitazon ikke bør anvendes som første linje behandling og understreget behovet for regelmæssige gennemgange af behandlingens fordele.
Patient selection criteria including that Pioglitazone should not be used as first line therapy and emphasising the need for regular review of treatment benefit.
Patient- fordeling
Patient
Patient- fordeling
Patient subset
Patient- population
Patient Population
Patient-brochure
Patient Brochures.
Patient-brochuren skal indeholde følgende nøgleelementer:
The patient brochure shall contain the following key elements:
Patient-ID:
Patient ID:
Patient-informationskort
Patient alert card
Patient-informationskort
Patient reminder card
Patient-informationskortet skal indeholde følgende hovedelementer:
The patient alert card shall contain the following key messages:
Patient-informationskortets rolle og anvendelse.
The role and use of patient alert card.
Patientadvarselskort
A Patient Alert Card
Patientadvarselskortet er specielt beregnet på at informere patienterne om nødvendigheden af at undgå graviditet og sikre, at de anvender effektive præventionsmetoder.
Patient Alert Card specifically aimed at informing patients of the need to avoid pregnancy and to ensure effective contraceptive measures are used.
Patientandel (%) med bevist/sandsynlig IFIs
Proportion (%) of patients with proven/probable IFIs
Patientandelen (%) med respons(hiv-1-RNA < 50 kopier/ml ved uge 24) over for PREZISTA co-administreret med ritonavir (600/100 mg to gange dagligt) efter genotype ved baselinea og
Proportion (%) of patients with response (HIV-1 RNA < 50 copies/ml at week 24) to PREZISTA co-administered with ritonavir (600/100 mg twice daily) by baseline genotypea, and baseline
Patientandelen (%)med respons(hiv-1-RNA < 50 kopier/ml ved uge 24) over for PREZISTA
Proportion (%) of patients with response (HIV-1 RNA < 50 copies/ml at week 24) to PREZISTA co-administered with ritonavir (600/100 mg twice daily) by baseline genotypea, and baseline
Patientandelen (%)med respons(hiv-1-RNA < 50 kopier/ml ved uge 24) over for PREZISTA co-administreret med ritonavir (600/100 mg to gange dagligt) efter genotype ved baselinea og
Proportion (%) of patients with response (HIV-1 RNA < 50 copies/ml at week 24) to PREZISTA co-administered with ritonavir (600/100 mg twice daily) by baseline genotypea, and baseline
Patientbrochurer
Patient booklets
Patientbrochurer
Patient Brochures
Patientdemografi (køn, alder og race) og karakteristika ved baseline var sammenlignelige for de grupper, der fik ISENTRESS 400 mg to gange dagligt, og placebogrupperne.
Patient demographics (gender, age and race) and baseline characteristics were comparable between the groups receiving ISENTRESS 400 mg twice daily and placebo.
Patientdemografi (køn, alder og race) og karakteristika ved baseline var sammenlignelige for den gruppe, der fik ISENTRESS 400 mg to gange dagligt og gruppen, der fik efavirenz 600 mg ved sengetid.
Patient demographics (gender, age and race) and baseline characteristics were comparable between the group receiving ISENTRESS 400 mg twice daily and the group receiving efavirenz 600 mg at bedtime.
Patientdemografi og sygdoms- karakteristika ved baseline var sammenlignelige behandlingsgrupperne imellem.
Patient demographic and baseline disease characteristics were similar between the treatment groups.
Patientdemografi og sygdomskarakteristika ved baseline var sammenlignelige behand- lingsgrupperne imellem.
Patient demographic and baseline disease characteristics were similar between the treatment groups.
Patientdemografien inkluderer en median baseline-hiv-1-RNA på 5,2 log10 kopier/ml og 5,1 log10 kopier/ml og et mediant baseline-CD4 celletal på 88 celler/mm3 og 97 celler/mm3 for hhv.
Patient demographics include a median baseline HIV-1 RNA of 5.2 log10 copies/ml and 5.1 log10 copies/ml and median baseline CD4 cell count of
Patientdemografiske og baseline-sygdomsegenskaber var sammenlignelige behandligsgrupperne imellem.
Patient demographic and baseline disease charateristics were similar between the treatment groups.
Patienten anbefales at have coitus samme dag og dagen efter Ovitrelle- injektionen.
The patient is recommended to have coitus on the day of, and the day after, Ovitrelle injection.
Patienten anbefales at have coitus samme dag og dagen efter Ovitrelle-injektionen.
The patient is recommended to have coitus on the day of, and the day after, Ovitrelle injection.
patienten anbefales.
Clinical monitoring of patients is recommended.
Patienten bekræfter, at han/hun forstår de førnævnte betingelser.
The patient confirms that he (she) understand the aforementioned conditions.
Patienten bør behandles indtil sygdomsprogression eller uacceptabel toksicitet.
Patients should be treated until disease progression or unacceptable toxicity.
Patienten bør derfor advares om, at der kan opstå forbigående svimmelhed og, at de i såfald ikke bør føre motorkøretøj eller anvende maskiner.
Patients must therefore be warned that transient dizziness may occur, in which case they should not drive or use machines.
Patienten bør desuden gives antibiotika i form af øjendråber før og efter injektionen og bør overvåges efter injektionen for at kontrollere eventuel forekomst af infektion eller forhøjet tryk i øjet.
Patients should also receive antibiotic eye drops before and after injection and they should be monitored after the injection to check for infection or raised eye pressure.
Patienten bør drøfte resultaterne af PET- skanningen med lægen.
Patients should discuss the results of their PET scan with their doctor.
Patienten bør faste i mindst fire timer inden prøven, således at prøven udføres på tom mave.
The patient should fast for at least 4 hours before the test so that the test is taken on an empty stomach.
Patienten bør have coitus på selve dagen og på dagen efter hCG indgivelsen.
The patient is recommended to have coitus on the day of, and the day following, hCG administration.
Patienten bør have coitus på selve dagen og på dagen efter hCG- indgivelsen.
The patient is recommended to have coitus on the day of, and the day following, hCG administration.
Patienten bør holdes under observation af lægen for akutte toksiske reaktioner.
Patients should be observed by the physician for immediate toxic reactions.
Patienten bør ikke bære mere end ét IONSYS-system ad gangen.
Patients should not wear more than one IONSYS at the same time.
Patienten bør ikke tage en ekstra dosis, hvis de ikke smager noget efter inhalation.
The patient should not take an extra dose if they do not taste anything after inhaling.
Patienten bør imidlertid informeres om, at der er rapporteret svimmelhed under behandling med dolutegravir.
However, patients should be informed that dizziness has been reported during treatment with dolutegravir.
Patienten bør indtage 0,5 ml opløsning (5 mg) (svarende til ét tryk på pumpen) dagligt i 7 dage.
The patient should take 0.5 ml solution (5 mg) equivalent to one pump actuation per day for 7 days.
Patienten bør indtage 1 ml opløsning (10 mg) (svarende til to tryk på pumpen) dagligt i 7 dage.
The patient should take 1 ml solution (10 mg) equivalent to two pump actuations per day for 7 days.
Patienten bør indtage 1,5 ml opløsning (15 mg) (svarende til tre tryk på pumpen) dagligt i 7 dage.
The patient should take 1.5 ml solution (15 mg) equivalent to three pump actuations per day for 7 days.
Patienten bør indtage 2 ml opløsning (20 mg) (svarende til fire tryk på pumpen) én gang dagligt i 7 dage.
The patient should take 2 ml solution (20 mg) equivalent to four pump actuations once a day.
Patienten bør indtage en 5 mg filmovertrukket tablet dagligt (hvid til grålighvid, oval-aflang) i 7 dage..
The patient should take one 5 mg film-coated tablet per day (white to off-white, oval-oblong) for 7 days.
Patienten bør indtage en 5 mg filmovertrukket tablet dagligt (hvid) i 7 dage.
The patient should take one 5 mg film-coated tablet per day (white) for 7days.
Patienten bør indtage en filmovertrukken 10 mg-tablet dagligt i 7 dage.
The patient should take 10 mg per day for 7 days.
Patienten bør indtage en filmovertrukken 10 mg-tablet dagligt i 7 dage.
The patient should take one 10 mg film-coated tablet per day for 7 days.
Patienten bør indtage en filmovertrukken 15 mg-tablet dagligt i 7 dage.
The patient should take 15 mg per day for 7 days.
Patienten bør indtage en filmovertrukken 15 mg-tablet dagligt i 7 dage.
The patient should take one 15 mg film-coated tablet per day for 7 days.
Patienten bør indtage en filmovertrukken 20 mg-tablet dagligt i 7 dage.
The patient should take one 20 mg film-coated tablet (20 mg) per day.
Patienten bør indtage en filmovertrukken 20 mg-tablet dagligt i 7 dage.
The patient should take one 20 mg film-coated tablet per day.
Patienten bør indtage en filmovertrukken 5 mg-tablet dagligt i 7 dage.
The patient should take 5 mg per day for 7 days.
Patienten bør indtage en filmovertrukken 5 mg-tablet dagligt i 7 dage.
The patient should take one 5 mg film-coated tablet per day for 7 days.
Patienten bør indtage en halv filmovertrukken 10 mg-tablet (5 mg) dagligt i 7 dage.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Patienten bør indtage en halv filmovertrukken 10 mg-tablet (5 mg) dagligt i 7 dage.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7days.
Patienten bør indtage en halv filmovertrukket 10 mg-tablet (5 mg) dagligt i 7 dage.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Patienten bør indtage halvanden filmovertrukne 10 mg-tabletter (15 mg) dagligt i 7 dage.
The patient should take one and a half 10 mg film-coated tablet (15 mg) per day for 7 days.
Patienten bør indtage halvanden filmovertrukne 10 mg-tabletter (15 mg) dagligt i 7 dage.
The patient should take one and a half 10 mg film-coated tablet (15 mg) per day for 7days.
Patienten bør indtage halvanden filmovertrukne 10 mg-tabletter (15 mg) dagligt i 7 dage.
The patient should take one and a half 10 mg film-coated tablet (15 mg)per day for 7 days.
Patienten bør indtage halvanden filmovertrukne 10 mg-tabletter (15 mg) dagligt i 7 dage.
The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Patienten bør indtage to filmovertrukne 10 mg-tabletter (20 mg) dagligt i 7 dage.
The patient should take two 10 mg film-coated tablets (20mg) per day.
Patienten bør indtage to filmovertrukne 10 mg-tabletter (20 mg) dagligt.
The patient should take two 10 mg film-coated tablets (20 mg) per day.
Patienten bør indtage én filmovertrukken 10 mg-tablet (10 mg) dagligt i 7 dage.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Patienten bør indtage én filmovertrukken 10 mg-tablet (10 mg) dagligt i 7 dage.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7days.
Patienten bør indtage én filmovertrukken 10 mg-tablet dagligt (bleggul til gul, oval) i 7 dage.
The patient should take one 10 mg film-coated tablet per day (pale yellow to yellow, oval shaped) for 7 days.
Patienten bør indtage én filmovertrukken 10 mg-tablet dagligt (hvid med delekærv) i 7 dage.
The patient should take one 10 mg film-coated tablet per day (white, scored) for 7days.
Patienten bør indtage én filmovertrukket 10 mg-tablet (10 mg) dagligt i 7 dage.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Patienten bør indtage én filmovertrukket 15 mg-tablet dagligt (grålig orange, oval-aflang) i 7 dage.
The patient should take one 15 mg film-coated tablet per day (greyorange, oval-oblong) for 7 days.
Patienten bør indtage én filmovertrukket 15 mg-tablet dagligt (orange-grålig orange) i 7 dage.
The patient should take one 15 mg film-coated tablet per day (orange to grey-orange) for 7days.
Patienten bør indtage én filmovertrukket 20 mg-tablet dagligt (grålig rød, oval-aflang) i 7 dage.
The patient should take one 20 mg film-coated tablet per day (grey-red, oval-oblong) for 7 days.
Patienten bør indtage én filmovertrukket 20 mg-tablet dagligt (svag –grålig rød) i 7 dage.
The patient should take one 20 mg film-coated tablet per day (pale red to grey-red, scored) for 7 days.
Patienten bør informeres om dette ved behandlings start.
The patient should be informed about this at the start of the treatment.
Patienten bør informeres om ikke at indtage Nevanac oralt.
Patients should be instructed not to swallow NEVANAC.
Patienten bør informeres om, at han/hun er blevet behandlet med Refludan.
Patients should be informed that they have received Refludan.
Patienten bør instrueres i, at eventuelle ekstra kanyler og renseservietter, der er tilbage efter sidste dosis er udtaget af pennen, skal smides ud på en passende og sikker måde.
Instruct the patient that any extra needles and swabs that remain after the final dose has been taken from the pen must be discarded appropriately and safely.
Patienten bør konsultere en læge før samtidig anvendelse af alli og antiretrovirale lægemidler.
Patients should consult a physician before taking alli concomitantly with antiretroviral medications.
Patienten bør normalt starte med to doser à 2,25 g (4,5 ml) pr. dag.
Patients should usually start with two doses of 2.25 g (4.5 ml) per day.
Patienten bør også rådes til at informere sine pårørende eller evt. plejepersonale om behandlingen, da de måske opdager symptomer, patienten ikke selv er klar over.
Patients should also be advised to inform their partner or caregivers about their treatment, since they may notice symptoms that the patient is not aware of.
Patienten bør omhyggeligt følge lægens instruktioner om basal infusionshastighed og bolusdoser, som skal tages ved måltiderne.
The patient should follow the instructions from the physician about the basal infusion rate and the mealtime insulin boluses to be taken.
Patienten bør opfordres til at læse brugsanvisningen i indlægssedlen omhyggeligt før OptiSet anvendes.
The patient should be advised to read the instructions for use included in the package leaflet carefully before using OptiSet.
Patienten bør oplyses om risikoen for interaktion med andre receptpligtige lægemidler og opfordres til at søge lægehjælp i tilfælde af svimmelhed, kvalme eller opkastning.
Inform the patient about the potential for an interaction with other prescribed medicinal products and to contact his/her doctor in case of dizziness, nausea or vomiting.
Patienten bør overholde den fosfatfattige kost, der er ordineret.
Patients should keep to their prescribed low- phosphate diets.
Patienten bør overvåges for
Patients should be
Patienten bør rådes til, at smide nålen ud efter hver injektion.
The patient should be advised to discard the needle after each injection.
Patienten bør sidde i en opret stilling under inhalation.
The patient should sit in an upright position during inhalation.
Patienten bør startes med en dosis på 45 mg om morgenen og 15 mg om aftenen (45+15 mg), og dosen bør derefter øges til 60+30 mg eller 90+30 mg afhængigt af, hvad patienten kan tolerere.
Patients should be started with a dose of 45 mg in the morning and 15 mg in the evening (45+15 mg), and the dose should then be increased to 60+30 mg or 90+30 mg, depending on what the patient can tolerate.
Patienten bør tage 0,5 ml opløsning (5 mg) dagligt, hvilket svarer til ét tryk på pumpen, i 7 dage.
The patient should take 0.5 ml solution (5 mg) equivalent to one pump actuation per day for 7 days.
Patienten bør tage 1 ml opløsning (10 mg) dagligt, hvilket svarer til to tryk på pumpen, i 7 dage.
The patient should take 1 ml solution (10 mg) equivalent to two pump actuations per day for 7 days.
Patienten bør tage 1,5 ml opløsning (15 mg) dagligt, hvilket svarer til tre tryk på pumpen, i 7 dage.
The patient should take 1.5 ml solution (15 mg) equivalent to three pump actuations per day for 7 days.
Patienten bør tage 2 ml opløsning (20 mg) én gang dagligt, hvilket svarer til fire tryk på pumpen.
The patient should take 2 ml solution (20 mg) equivalent to four pump actuations once a day.
Patienten bør tage en filmovertrukket 10 mg-tablet dagligt i 7 dage.
The patient should take one 10 mg film-coated tablet per day for 7 days.
Patienten bør tage en filmovertrukket 15 mg-tablet dagligt i 7 dage.
The patient should take one 15 mg film-coated tablet per day for 7 days.
Patienten bør tage en filmovertrukket 20 mg-tablet dagligt.
The patient should take one 20 mg film-coated tablet per day.
Patienten bør tage en filmovertrukket 5 mg-tablet dagligt i 7 dage.
The patient should take one 5 mg film-coated tablet per day for 7 days.
Patienten bør tage en halv 10 mg filmovertrukket tablet (5 mg) dagligt i 7 dage.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Patienten bør tage en halv filmovertrukket 10 mg-tablet (5 mg) dagligt i 7 dage.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Patienten bør tage fire filmovertrukne 5 mg-tabletter (20 mg) dagligt.
The patient should take four 5 mg film-coated tablets (20 mg) per day.
Patienten bør tage halvanden 10 mg filmovertrukket tablet (15 mg) dagligt i 7 dage.
The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Patienten bør tage halvanden filmovertrukket 10 mg-tablet (15 mg) dagligt i 7 dage.
The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Patienten bør tage to 10 mg filmovertrukne tabletter (20 mg) dagligt.
The patient should take one 20 mg film-coated tablet (20 mg) per day.
Patienten bør tage to 10 mg filmovertrukne tabletter (20 mg) dagligt.
The patient should take two 10 mg film-coated tablets (20 mg) per day.
Patienten bør tage to filmovertrukne 10 mg-tabletter (20 mg) dagligt.
The patient should take two 10 mg film-coated tablets (20 mg) per day.
Patienten bør tage to filmovertrukne 5 mg-tabletter (10 mg) dagligt i 7 dage.
The patient should take two 5 mg film-coated tablets (10 mg) per day for 7 days.
Patienten bør tage tre filmovertrukne 5 mg-tabletter (15 mg) dagligt i 7 dage.
The patient should take three 5 mg film-coated tablets (15 mg) per day for 7 days.
Patienten bør tage én 10 mg filmovertrukket tablet (10 mg) dagligt i 7 dage.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Patienten bør tage én 10 mg filmovertrukket tablet dagligt (hvide til off-white, kapselformede, bikonvekse tabletter med en delekærv på den ene side og præget med ”10” på den anden side) i 7 dage.
The patient should take one 10 mg film-coated tablet per day (white to off-white, capsule shaped, biconvex tablets with a break score on one side and embossed with “10” on the other side.) for 7 days.
Patienten bør tage én 10 mg filmovertrukket tablet dagligt i 7 dage.
The patient should take one 10 mg film-coated tablet per day for 7 days.
Patienten bør tage én 10 mg filmovertrukket tablet pr. dag (bleggul til gul, oval) i 7 dage.
The patient should take one 10 mg film-coated tablet per day (pale yellow to yellow, oval shaped) for 7 days.
Patienten bør tage én 10 mg filmovertrukket tablet pr. dag i 7 dage.
The patient should take one 10 mg film-coated tablet per day for 7 days.
Patienten bør tage én 15 mg filmovertrukket tablet dagligt (hvide til off-white, kapselformede, bikonvekse tabletter, glatte på den ene side og præget med ”15” på den anden side) i 7 dage.
The patient should take one 15 mg film-coated tablet per day (white to off-white, capsule shaped, biconvex tablets plain on one side and embossed with “15” on the other side.) for 7 days.
Patienten bør tage én 15 mg filmovertrukket tablet dagligt i 7 dage.
The patient should take one 15 mg film-coated tablet per day for 7 days.
Patienten bør tage én 15 mg filmovertrukket tablet pr. dag (gråligorange, oval-aflang) i 7 dage.
The patient should take one 15 mg film-coated tablet per day (grey-orange, oval-oblong) for 7 days.
Patienten bør tage én 15 mg filmovertrukket tablet pr. dag i 7 dage.
The patient should take one 15 mg film-coated tablet per day for 7 days.